Document Detail

The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
MedLine Citation:
PMID:  21951944     Owner:  NLM     Status:  MEDLINE    
Debate continues about the optimal treatment modality of lupus nephritis (LN). We compared the efficacy and safety of intravenous cyclophosphamide (CYC) and mycophenolate mofetil (MMF) for LN treatment in Korea. After searching for systemic lupus erythematosus (SLE) patients diagnosed between 1998 and 2007 with the diagnostic code of ICD10, we selected the 71 patients who were treated with CYC or MMF without any other immunosuppressant except systemic steroid. Composite outcome was defined as progression to end-stage renal disease (ESRD) and/or all-cause mortality. The initial manifestations of the CYC group were more severe than those of the MMF group. The mean daily MMF dose was 980  ±  100  mg for 21.67  ±  18.25 months. The mean monthly dose per CYC pulse therapy was 850  ±  30  mg for 17.04  ±  13.15 months. The incidence of composite outcome was 5/20 (25%) in the MMF group and 4/51 (7.8%) in the CYC group. The relative risk (RR) for composite outcome in the CYC group was 0.249 (95% CI for RR: 0.067-0.934, p = 0.039) compared with the MMF group with Cox's hazard proportional analysis. In Kaplan-Meier analysis, the probability of composite outcome was lower in the CYC group than in the MMF group (Log rank test p-value = 0.026). The results of this retrospective study suggest that intravenous CYC therapy may be more efficacious in averting ESRD and death than MMF. These results need to be confirmed in a larger randomized controlled trial.
H S Koo; Y C Kim; S W Lee; D K Kim; K-H Oh; K W Joo; Y S Kim; C Ahn; J S Han; S Kim; H J Chin
Related Documents :
2745534 - Vascular injuries caused by anti-personnel mines.
9440454 - Free versus pedicled omental grafts for limb salvage in buerger's disease.
18220314 - Reconstructive microsurgery in pediatric population-a series of 25 patients.
7813724 - Perioperative outcome of acute lower limb ischaemia on the basis of the national vascul...
22367794 - Prospective randomized trial of preoperative enteral immunonutrition followed by electi...
21846874 - Assessing the influence of mandibular prominence on perceived attractiveness in the ort...
Publication Detail:
Type:  Journal Article     Date:  2011-09-27
Journal Detail:
Title:  Lupus     Volume:  20     ISSN:  1477-0962     ISO Abbreviation:  Lupus     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-18     Completed Date:  2012-03-09     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9204265     Medline TA:  Lupus     Country:  England    
Other Details:
Languages:  eng     Pagination:  1442-9     Citation Subset:  IM    
Department of Internal Medicine, Inje University College of Medicine, South Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cyclophosphamide / therapeutic use*
Disease Progression
Immunosuppressive Agents / therapeutic use*
Kaplan-Meier Estimate
Kidney Failure, Chronic / drug therapy*,  mortality,  physiopathology,  prevention & control
Lupus Nephritis / drug therapy*,  mortality*,  physiopathology
Middle Aged
Mycophenolic Acid / analogs & derivatives*,  therapeutic use
Retrospective Studies
Young Adult
Reg. No./Substance:
0/Immunosuppressive Agents; 24280-93-1/Mycophenolic Acid; 50-18-0/Cyclophosphamide; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-a...
Next Document:  The involvement of immune semaphorins and neuropilin-1 in Lupus Nephritis.